Do GLP-1–Based Therapies Increase Cancer Risk?
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Cases of pancreatitis have been de-scribed in connection with the useof exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 re-ceptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with re-spective agonists has a potential to cause pancreatitis, perhaps chronic pancreati-tis, and in the long term, potentially even pancreatic cancer (3–5). Further-more, in rodents like mice and rats, stim-ulating the GLP-1 receptor raises cAMP in thyroid C cells, initiates the release of cal-citonin, and upon longer-term exposure, is accompanied by C-cell proliferation and the formation of C-cell adenomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is evidence that GLP-1 analogues increase the risk of medullary thyroid cancer, which is a cause for concern.268”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [268]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“For the purpose of this review, GLP-1–based therapies are GLP-1 receptor agonists such as exenatide, liraglutide, and others or dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin (8).”
BackgroundSelf-citationVincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“It takes another 7 years (approximately) for such cells to develop subclones with metastatic capacity and another 3 years (approximately) before the disease will be diagnosed due to clinical symptoms and a clinically apparent primary tumor accompanied by metastases (13).”
BackgroundUnder-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 8×
“(3), we looked at subcategories of malignant disease entities.”
BackgroundMethodInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“C-cell disease ranges from C-cell hyperplasia to C-cell adenoma and medullary carcinoma (6).”
BackgroundInfluentialDeterminants of Under-Reporting of Adverse Drug Reactions: A Systematic Review
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00002 · Cited by 574
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“In mice and rats, a once-daily injection of liraglutide, a GLP-1 receptor agonist that has an approximate half-life of 13 h, leads to permanently elevated circulating drug concentrations (32,33) and increased rate of C-cell abnormalities in both mice and rats, with some animals developing C-cell carcinomas, especially…”
Background
Cited by
Items 101–151 of 151
Lafferty, R. A., Tanday, N., Flatt, P. R., & Irwin, N. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154339 · Cited by 11
Marasinghe, D. H., Butalia, S., Garies, S., Drummond, N., Kim, J. W., & Senior, P. A. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.02.002 · Cited by 12
Semaglutide once-weekly: improved efficacy with a new safety warning
Coon, S. A., Crannage, E. F., Kerwin, L. C., & Guyton, J. E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1534201 · Cited by 10
Familial thyroid carcinoma: the road less traveled in thyroid pathology – an update
LiVolsi, V. A., Baraban, E. G., & Baloch, Z. W. (2017) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2017.06.004 · Cited by 9
Pancreatitis and incretin-based drugs: clarity or confusion?
Nauck, M. A., & Meier, J. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70186-4 · Cited by 6
Self-citationHtike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Shirakawa, J., & Terauchi, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13192 · Cited by 6
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“However, the clinical relevance of this finding in humans remains debated, as GLP-1 receptor expression on thyroid C-cells is substantially lower in humans than in rodents, limiting direct extrapolation [150].”
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9351-6 · Cited by 5
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedPancreatic Diseases and Diabetes
Unnikrishnan, R., & Mohan, V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch21 · Cited by 5
Fournier, M., Germé, M., Theobald, K., Scholz, G. H., & Lehmacher, W. (2014) · PubMed Central · doi:10.3205/000199 · Cited by 5
“While an analysis of data from the FDA AE reporting system did seem to show an increased risk of pancreatic and thyroid cancer with incretin therapies, the data were inconsistent and have been discredited on the basis of a bias in reporting of events [32], [33].”
MethodGlasgow, K., Jiminez, V. S., Garcia, N., & Gillis, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33420 · Cited by 3
“Upon drug approval, the FDA requires systematic monitoring of the incidence of malignancies related to medications, including MTC related to new GLP-1 receptor agonists [15].”
BackgroundDayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Alfaifi, M., Alghadeer, S. M., & Alwhaibi, A. M. (2025) · Healthcare · doi:10.3390/healthcare13151827 · Cited by 4
“Some studies, including meta-analyses, suggest a minimal increase, while others do not [19–22].”
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 3
Williams, J. A. (2014) · doi:10.3998/panc.2014.7 · Cited by 4
Jaradat, J. H., Alahmad, R., Jaghbeer, M. A., Abdelaziz, A. A., Afifeh, N. A., Afifeh, G. A., Rao, A., Alzoubi, A., & Nashwan, A. J. (2025) · Cureus · doi:10.7759/cureus.96071 · Cited by 3
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Breite, L. D., Steck, M., Cutshall, B. T., Shah, S. P., & Cave, B. E. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100736 · Cited by 3
Dinda, B., & Saha, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-92196-5_1 · Cited by 2
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 2
“A second look of the results in 2013 argued that there were significant limitations in the analysis of the data and disputed the accuracy of the evidence [93].”
GLP-1 receptor agonists and the risk of colorectal cancer
Kakkar, A. K. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.03.028 · Cited by 2
AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES
Ismail, R., Anter, A. F., Matouk, A. I., & Heeba, G. H. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.160122.1493 · Cited by 2
Patel, D. (2026) · Cureus · doi:10.7759/cureus.107202 · Cited by 2
“Class warnings related to thyroid C-cell tumors are based on GLP-1R biology and rodent findings, so labeling may still apply depending on regulatory decisions [54,87].”
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
“…diabetesor obesity) that is a PDAC risk factor), detection (e.g., overreporting due to additional testing to rule out a suspected adverse event (e.g., imaging triggered by pancreas enzyme elevations)), and Weber effect (initial increase in event reporting shortly after drug launch) 49 .”
Sun, Y., Liu, B., Loh, H., Mathialagan, S., Lin, C. H.-T., Tarabichi, Y., Veccia, D., Wong, R., Tse, W. W., & Song, G. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16090478 · Cited by 1
“Expert opinion suggests that a minimum of 5–6 years of follow-up is required to meaningfully assess pancreatic cancer risk [29].”
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
Type 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
GLP-1-Rezeptor-Agonisten und kardiovaskuläre Outcomes: Eine Metaanalyse
Chakaroun, R. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0304-4
Krajewska, J., Krajewski, W. R., & Zatoński, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_59
Cytoprotection by Melatonin: The Metabolic Syndrome as an Example
Cardinali, D. P., & Vigo, D. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_22
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3
Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1
Williams, J. A. (2021) · doi:10.3998/panc.2021.06
Nanoparticle-assisted oral delivery of small and large peptides
Arora, M., Zou, D., & Kumar, M. N. V. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821061-1.00007-1
Chapter 7: Therapy for Type 2 Diabetes
Valentine, V. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch07
Chapter 32: Diabetes and Cancer
Cypress, M. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch32
Wojciechowska, J. K., Krajewski, W. R., Zatoński, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_63
INCIDÊNCIA DE PANCREATITE AGUDA DEVIDO AO USO DE AGONISTAS DO RECEPTOR DE GLP-1
Silva, V. F., de Lima, J. A., Lopes, A. G. B., Valerio, L. P., & Valerio, H. P. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i9.5669 · Cited by 1
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
Stiewig-Rapp, M., & Basheer, H. (2025) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2025.1000021
The Potential Role of GLP-1 Receptor Agonists for the Treatment of Alzheimer’s Disease
Oyang, T. (2025) · American journal of student research. · doi:10.70251/hyjr2348.36594600
The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review
Hatzis, G., McKennitt, A., Gerber, B. S., Quinn, R., & Lee, J. A. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag044
Diabetes and cancer: clinical implications for integrated metabolic–oncologic care
Fuchs-Tarlovsky, V. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1824109
GLP-1 RECEPTOR AGONISTS IN HUMAN CANCERS: A NARRATIVE LITERATURE REVIEW
Rizopoulos, T. (2026) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2026.31.3.2484
Den, J., Nelson, N., Vaghjiani, R. G., & Klimberg, V. S. (2026) · Journal of Surgical Oncology · doi:10.1002/jso.70411 · Cited by 1
Kukeev, I., Arnon, Y., Quint, E., Freih, S. A., Osyntsov, A., & Dukhno, O. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005470
Metadata
- Authors
- Nauck, M. A., & Friedrich, N.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Universität Greifswald (DE)
- Corresponding author
- Friedrich, Nele
- ORCID
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S245-S252
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3920789
- OpenAlex
- W2158762809
- Cited by
- 145
- References
- 56
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 17 · 2016: 12 · 2015: 13 · 2014: 17 · 2013: 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, exenatide, liraglutide, pancreatitis, chronic pancreatitis, pancreatic cancer, thyroid C cells, calcitonin, cAMP signaling, cancer risk
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, Risk Factors, Thyroid Neoplasms, Glucagon-Like Peptide 1, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.